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Introduction
Age-related diseases are becoming a growing burden on devel-
oped societies presenting a major health challenge with signifi-
cant socio-economic consequences. Herpes zoster (HZ) affects 
more than 500,000 older adults in the US1 and approximately 
290,000 adults aged over 50 years in Germany every year.2 In 
Switzerland, data from the national sentinel surveillance network 
indicate that the annual incidence of HZ among the 50+ popu-
lation ranges between 0.31% and 0.82%, resulting in approxi-
mately 11,000 new Swiss HZ patients aged 50+ every year.3
HZ results in major morbidity for a substantial number of 
individuals through its most severe and painful complication, 
post-herpetic neuralgia (PHN). HZ is caused by reactivation 
of the varicella zoster virus (VZV) in the dorsal root ganglia of 
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individuals having had a primary VZV infection and is associ-
ated with age-related normal decrease in varicella zoster-specific 
cell-mediated immunity.
The total lifetime risk of HZ is 25%4 with the incidence almost 
doubling with every decade after the age of 50.5 HZ symptoms 
include numbness, itching and pain during the prodromal phase, 
followed by painful unilateral vesicular eruptions on the skin that 
last for approximately 3–4 weeks.6 However, painful symptoms 
can persist for months or years after the cutaneous eruption has 
healed in about 20% to 25% of HZ cases,7 i.e., developing the 
chronic pain syndrome PHN. PHN is clinically defined as pain 
occurring or persisting at least 1 or 3 months after rash onset. 
While there is no international consensus on PHN definition, 
the most commonly accepted one is that of 3 months.6,8,9 PHN 
is associated with considerable reduction in quality of life with 
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Resulting ICERs are 25,538 
CHF (23,646 USD) per QALY 
gained, 6,625 CHF (6,134 USD) 
per HZ avoided and 15,487 CHF 
(14,340 USD) per PHN3 case 
avoided. From a societal perspec-
tive, results are 28,544 CHF 
(26,430 USD) per QALY gained 
7,405 CHF (6,856 USD) per HZ 
case avoided and 17,310 CHF 
(16,028 USD) per PHN3 case 
avoided.
31 and 73 people would need to 
be vaccinated to prevent one case 
of HZ and PHN, respectively.
Sub-group analyses. Sub-
group analyses were conducted 
for the 60–69, 65+ and 70+ age-
groups showing that vaccination is 
most cost-effective in the younger 
60–69 group and least cost-
effective in the older 70+ group, 
mainly due to decreased vaccine 
protection and increased mortal-
ity in this age group. In particular, 
ICERs are 18,089 CHF per QALY 
gained in the 60–69 group, 26,083 
CHF per QALY gained in the 65+ 
group and 30,934 CHF per QALY 
gained in the 70+ group, from a 
TPP perspective. From the societal 
perspective the corresponding results for the three age-groups are 
19,998 CHF per QALY gained 29,104 CHF, per QALY gained 
and 34,543 CHF per QALY gained respectively.
Sensitivity analyses. As shown in Figure 2, ICERs are most 
sensitive to discount rates, HZ incidence data and vaccine price. 
Discount rates of 5% for both costs and benefits will result in the 
highest ICERs, while the use of an alternative source for HZ inci-
dence will produce the lowest ICERs. A change in the resource 
utilization cost has a marginal effect, while a change in the vac-
cine coverage rate does not have any effect on the cost-effective-
ness results, as outcomes and costs increase at a proportional rate 
depending on the coverage rates selected.
Methods
A health-economic model was originally11 developed for the 
UK to assess the lifetime clinical and economic impact of the 
vaccine. The model, validated successfully by comparison of 
its results to the SPS trial data, demonstrated that a vaccina-
tion strategy for those aged 50+ would result in reduced num-
bers of HZ and PHN cases and substantial economic benefits, 
thus being cost-effective. It was adapted to the Swiss situation in 
order to compare the adoption of a vaccination policy targeting 
the immunocompetent population aged 70–79 years to the cur-
rent policy of no vaccination, applying a realistically achievable 
many patients developing severe physical, occupational and social 
disabilities as a consequence of the enduring pain.7,10
The efficacy of a new live attenuated vaccine, Zostavax®, 
has been tested in a large randomized, double-blind, placebo-
controlled trial (Shingles Prevention Study, SPS).9 In Europe, 
Zostavax® is indicated for the prevention of HZ and PHN in 
adults aged over 50 years.
The objective of this study is to explore the cost-effectiveness 
of a VZV universal vaccination strategy of adults aged 70–79 
years in Switzerland, considered as an important piece of infor-
mation for successful market access.
Results
Base case. The model predicts that vaccinating 20% of the 
Swiss population aged 70–79 years would result in 3,412 fewer 
cases of HZ, 1,460 fewer PHN3 cases and 885 additional 
QALYs over the lifetime of this population, compared to the 
current policy of no vaccination. Additional costs of a vaccina-
tion strategy equal 22.6 million CHF and 25.3 million CHF, 
under a TPP and a societal perspective respectively. On average, 
a patient in the vaccination policy is associated with a lifetime 
cost of 108.84 CHF under a TPP perspective and 99.78 CHF 
under a societal perspective versus 61.30 CHF and 57.25 CHF 
in the non-vaccination policy.
Figure 1. Model Health States.
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pharmacological and non-pharmacological treatments, diag-
nostic tests, as well as number of work-days lost due to HZ and 
PHN. In this context, it was estimated that approximately 20% 
of HZ patients with severe pain miss 21 days of work while 
20–30% of PHN patients miss 10–21 days of work depending 
on pain severity.14
In Switzerland, health care costs are partially reimbursed. 
There is an annual minimum deductible of 300 CHF, i.e., the 
“franchise” and a 10% charge for all outpatient medical costs 
exceeding the “franchise”. As the model population is relatively 
old and, therefore, more frequent consumers of health care, it was 
assumed that the “franchise” has already been reached, regardless 
of whether the population will have HZ or PHN. Outpatient 
visit costs were estimated using expert opinion. Drug costs were 
obtained from the Swiss “Compendium”, diagnostic test costs 
from TARMED, while n°272 and n°18 DRG costs were used 
to account for HZ and PHN hospitalization costs. Productivity 
losses were estimated using the human capital approach and 
applying data from the Swiss Federal Statistics Office.13 Hence, 
the average overall cost of an HZ episode ranged (no and severe 
pain respectively) between 362 CHF-1,227 CHF from the TPP 
perspective and 403 CHF-1,874 CHF from a societal perspec-
tive, while the average monthly cost of a PHN episode ranged 
(mild, severe pain respectively) between 127 CHF-1,532 CHF 
and 389 CHF-2,493 CHF under each perspective, respectively.14
Epidemiology. Data on HZ incidence was obtained from 
the Swiss Sentinel Surveillance Network which is a coopera-
tive surveillance project of the Federal Office of Public Health 
and the participating Swiss physicians, consisting of a conve-
nience sample of 150 to 250 general practitioners, internists and 
pediatricians.3,12
In the absence of suitable data on PHN proportion and HZ/
PHN gender split, the model employed information from the 
UK GPRD study15 which was developed to populate the UK 
analysis.11 The GPRD study estimated HZ and PHN data by 
age-group, based on a sample of 27,225 immunocompetent UK 
patients. GPRD provided data using both 1-month and 3-months 
definition of PHN and calibration was required before entering 
these data in the model. However, as this concerned non-Swiss 
data, impact of using UK data was explored in sensitivity analy-
ses. In addition, the GPRD study indicated no mortality directly 
linked to HZ or PHN, further confirmed by the lack of literature 
on the subject, as well as expert opinion. As no information was 
available for Switzerland, the same assumption was applied in the 
Swiss analysis.
Moreover, information from the SPS trial9 and literature16 was 
used to populate selected input parameters such as pain split, 
PHN duration and HZ recurrence rates.
Vaccination data. Vaccine efficacy, obtained from the SPS 
trial,9 is expected to offer lifetime protection against HZ and 
PHN. However, vaccine duration of protection is not known 
yet. While vaccine efficacy may diminish over time, long-term 
trial results are not yet sufficient to accurately document this, 
though more reliable data may become available in the future. 
Vaccination is assumed to have both direct and indirect effects 
on HZ and PHN. The direct effect is obtained through the 
coverage rate. Additional subgroup analyses were conducted 
for other age-groups of interest, i.e., the 60–69, 65+ and 75+ 
age-groups. Model outcomes, assessed over the lifetime of the 
study population, include total costs, quality-adjusted life-years 
(QALYs) gained, as well as HZ cases and PHN cases avoided (see 
Appendix).  In addition the number needed to vaccinate (NNV) 
quantifying the number of people that need to be vaccinated to 
prevent one case of HZ or PHN has been estimated. Incremental 
cost-effectiveness ratios (ICERs) are calculated by dividing the 
difference in total costs between the two policies by the differ-
ence in effectiveness. Cost per QALY gained, cost per HZ case 
avoided, and cost per PHN case avoided are calculated under 
both a third-party payer (TPP) and a societal perspective. The 
TPP perspective includes all health care related expenses, while 
the societal perspective includes also productivity losses due to 
work absenteeism and co-payments.
The model takes into account ageing of the population over 
the duration of the analysis, adjusting for changes in mortality, 
the likelihood of contracting HZ and PHN and vaccine efficacy, 
depending on age.
Model structure. The model11 uses a Markov process to simu-
late the lifetime incidence and consequences of HZ among the 
Swiss population aged 50+. The base case analysis is focusing on 
the population aged 70–79. The cohort is analyzed in separate 
5-year age-groups, by applying a matrix of transition probabilities 
to the different health states (Fig. 1). The lifetime of the cohort is 
divided into monthly Markov cycles. Within each cycle, cohort 
members may remain in their current health state or transition to 
one of the allowable states: “Healthy” (i.e., no HZ symptoms), 
“HZ”, “PHN” and “Death”. “HZ” and “PHN” health states are 
further divided into different pain severity levels (i.e., mild, mod-
erate or severe). “Recurrent HZ” and subsequent PHN states are 
also included but are constrained to single recurrent episodes. 
Cohort cycle’s members through the model eventually reaching 
death, based on Swiss age-specific mortality rates.
Using a monthly cycle length requires that all model inputs 
reflect their corresponding monthly values. Therefore, the 
1-month definition of PHN (PHN1) has been employed in the 
modeling process. However, given that the 3-month definition of 
PHN (PHN3) is most commonly accepted, the model has been 
adjusted to produce results according to PHN3.
Model inputs. Input parameters used in the model (Tables 1 
and 2) are derived from a range of sources, such as the Swiss sen-
tinel surveillance network,3,12 national statistics,13 the SPS trial,9 
published literature and a Swiss HZ and PHN burden of illness 
study.14
Management of HZ/PHN. All data related to HZ and PHN 
management in Switzerland were sourced from a Swiss burden 
of illness study,14 commissioned to inform the present analysis. It 
was based on two expert’s opinion, both experienced in HZ and 
PHN management in Switzerland.
The objective of the study was to investigate the health care-
related resource use due to HZ and PHN, by pain severity level 
and economic perspective, i.e., societal and TPP, using both 
definitions of PHN (1- and 3-months). In particular the study 
reported detailed information on outpatient and inpatient care, 
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Sensitivity analyses. The base case results variability to alter-
native values of key input parameters was explored by varying 
these within feasible ranges in one-way sensitivity analyses. Thus, 
the effects of alternative values of discount rates, HZ incidence,2,20 
PHN proportion,2 vaccine coverage rate, waning immunity,21 
duration of vaccine efficacy, vaccine price, health care costs and 
utility decrements,9,17,22 on results were explored.
Conclusion
The model predicts that from both TPP and societal perspec-
tive, the adoption of a vaccination policy in Switzerland for adults 
aged 70–79 years would result in a reduction of HZ and PHN 
cases and an improvement of health-related quality of life in the 
form of increased number of QALYs. Sensitivity analyses showed 
that although results are sensitive to certain parameters, such as 
discount rates and the choice of epidemiological data, the model 
is robust to change, providing reliable estimates of the QALYs 
and costs associated with HZ and PHN. In addition, ICERs 
remained below commonly accepted thresholds for all determin-
istic sensitivity analyses.
Resulting ICERs are comparable to those of other vaccination 
strategies implemented in Switzerland and are within the com-
monly accepted cost-effectiveness thresholds in Europe, suggest-
ing that such a vaccination strategy would be cost-effective in the 
Swiss setting.23,24
Strengths and limitations of the model have been previously 
described in the original discussion of the UK analysis.11 However, 
there are some limitations specific to this Swiss analysis, which 
reduction in the number of HZ and PHN cases. The indirect 
effect, relates only to PHN, and refers to the further reduction of 
PHN cases obtained through the reduced number of HZ cases.
Zostavax®’s efficacy has been studied in the pivotal SPS trial.9 
Compared to placebo, Zostavax® significantly reduces by 61% 
[95% CI: 51–69%] the HZ burden of illness, by 67% PHN inci-
dence [95% CI: 48–79%] and by 51% [95% CI: 44–58%] the 
HZ incidence. Zostavax® also prevents 73% [95% CI: 46–87%] 
of zoster cases with severe and long-lasting pain.
Efficacy in reducing the burden of illness and PHN incidence 
has been demonstrated to remain stable regardless of age, whereas 
reduction of HZ incidence was shown to be significantly higher 
in the younger age-group (i.e., 60–69).
A 20% coverage rate was assumed in the absence of relevant 
data. Vaccine administration costs were included, assuming that 
all patients would be vaccinated during a routine visit. In addition, 
it was assumed that 30% of patients would receive Zostavax® and 
the influenza vaccine at the same visit, and therefore cost-sharing 
of administration costs was applied.
Other inputs. Demographic and general mortality data were 
obtained from national statistics13 by 5-year age group and gender.
For the calculation of QALYs, utility weights associated with 
the different HZ and PHN pain states were obtained from lit-
erature.17 In lieu of country-specific data, UK age-specific utili-
ties were used to adjust for the fact that healthy and subsequent 
states would be affected by the age of the population under 
consideration.
Discount rates of 3.5% for costs and 1.5% for outcomes 
(QALYs) were applied in the model.18,19
Figure 2. Univariate sensitivity analyses: tornado diagram.
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population are essential. Effect of using UK parameters was tested 
in sensitivity analysis. Furthermore, disease-specific utility decre-
ments were obtained from a US population.17 However, accord-
ing to expert opinion, (Professor Mike Drummond: personal 
communication) while age-specific utilities may vary between 
are mainly related to the availability of country-specific data. No 
accurate Swiss information was available for the proportion of 
PHN and therefore the model applied UK data. As the PHN 
proportion together with HZ incidence represent the main driv-
ers of the model results, the use of values specific to the Swiss 
Table 1. Input data: epidemiology, utilities and vaccine characteristics
Base case Sensitivity analysis
HZ PHN HZ PHN
Epidemiology
Annual HZ Incidence (per 1,000  
people)/PHN1 Proportion per HZ case
Swiss sentinel 
 surveillance12
Gauthier 200815
Gauthier 200815/
Edmunds 200120
Edmunds 200120
Age 50–54 3.06 10.3% 3.44/4.61 7.40%
Age 55–59 3.06 13.7% 4.08/5.21 7.40%
Age 60–64 4.14 15.7% 4.9/5.92 21.20%
Age 65–69 4.14 18.7% 5.96/6.70 21.20%
Age 70–74 5.99 22.5% 6.34/7.53 28.60%
Age 75–79 5.99 26.6% 7.09/8.42 28.60%
Age 80–84 7.48 28.9% 7.29/9.37 34.40%
Age 85–89 7.48 25.9% 6.22/11.58 34.40%
Age 90+ 8.17 25.9% 6.22/11.58 34.40%
Mean Duration (in months) Oxman 20059 Gauthier 200815
Age ≤ 69 1.0 8.3 - 10.9
Age ≥ 70 1.0 10.9 - 11.0
Gender split Gauthier 200815
% female 61% 65%
Pain severity split at diagnosis Oxman 20059 Gauthier 200815
Age ≤ 69
No pain 27% - 65% -
Mild pain 41% 42% 24% 47%
Moderate pain 18% 9% 4% 42%
Severe pain 14% 49% 8% 11%
Age ≥ 70
No pain 26% - 45% -
Mild pain 32% 17% 41% 34%
Moderate pain 23% 16% 5% 54%
Severe pain 19% 67% 3% 12%
Quality of life
Utility Decrements Oster 200517 Bala 199822 Bala 199822
No pain 0.00 - 0.00 0.00
Mild pain 0.31 0.31 0.27 0.27
Moderate pain 0.42 0.42 0.40 0.40
Severe pain 0.75 0.75 0.53 0.53
Vaccine characteristics Oxman 20059
Efficacy: total % reduction in cases (PHN direct effect)
Age ≤69 63.90% 65.70%
Age ≥70 37.60% 66.85%
Efficacy: number of months reduction of PHN pain
Age ≤69 - -2.2
Age ≥70 - -3.3
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resulting in considerable costs from both a TPP and a societal 
perspective. This study attempts to estimate the health-economic 
impact of vaccinating older adults against these conditions, indi-
cating that a vaccine which is able to prevent HZ and PHN and 
reduce their severity can be considered a cost-effective investment 
of health care resources in Switzerland.
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countries, disease-specific decrements can be considered transfer-
able, thus the applied decrements17 are suitable for this analysis. 
Again, effect of using alternative decrements was tested in sen-
sitivity analyses, showing a moderate impact on results. Finally, 
resource use and cost data were obtained from a study based on 
Swiss expert opinion14,25 rather than on actual patient-level data, 
limiting to some extent the predictive model strength and the 
results’ generalization to the whole population. Nevertheless, a 
sensitivity analysis which varied all health care costs 20% above 
and below their base case value demonstrated that this parameter 
had only a marginal effect on results (2.5% decrease and increase 
compared to base case, respectively).
HZ and PHN can be extremely painful conditions affect-
ing patients’ quality of life over an extended period of time and 
Table 2. Input data: management costs, productivity costs and vaccination costs
Base case HZ PHN
Management costs—TPP 
 perspective
Michel 200614
No pain Mild Moderate Severe Mild Moderate Severe
outpatient visits CHF 127 CHF 127 CHF 127 CHF 289 CHF 117 CHF 117 CHF 373
Diagnostic tests CHF 44 CHF 53 CHF 53 CHF 53 CHF 2 CHF 2 CHF 2
Medications CHF 191 CHF 191 CHF 206 CHF 256 CHF 8 CHF 15 CHF 91
Non pharmacologic treatments - - - CHF 81 - CHF 95 CHF 324
Hospitalisations - - - CHF 548 - CHF 371 CHF 742
Working days loss (WDL) - - - - - - -
total CHF 362 CHF 371 CHF 386 CHF 1,227 CHF 127 CHF 600 CHF 1,532
range for sensitivity analysis: ±20%
Management costs—Societal 
perspective
Michel 200614
No pain Mild Moderate Severe Mild Moderate Severe
outpatient visits CHF 142 CHF 142 CHF 142 CHF 322 CHF 130 CHF 130 CHF 414
Diagnostic tests CHF 49 CHF 59 CHF 59 CHF 59 CHF 2 CHF 2 CHF 2
Medications CHF 212 CHF 212 CHF 229 CHF 285 CHF 15 CHF 27 CHF 128
Non pharmacologic treatments - - - CHF 90 - CHF 105 CHF 360
Hospitalisations - - - CHF 609 - CHF 412 CHF 825
Working days loss (WDL) - - - CHF 509 CHF 242 CHF 364 CHF 764
total CHF 403 CHF 413 CHF 430 CHF 1,874 CHF 389 CHF 1,040 CHF 2,493
range for sensitivity analysis: ±20%
Employment Males Females
Age 60–64 74.90% 56.60% Federal statistics office of Switzerland13
Age 65–69 38.41% 21.64% Federal statistics office of Switzerland13
Age 70+ 0% 0% Assumption
Productivity costs Federal statistics office of Switzerland13
Average daily wage rate CHF 302.7
Vaccination costs Sensitivity Analysis
Unit cost Assumption
one dose of vaccine CHF 240.7 -10% +10% CHF 188.4 -
Administration cost Assumption
CHF 25.2 - - - CHF 0.0
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To further illustrate the potential benefit of VZV vaccination, 
the NNV or Number Needed to Vaccinate results are calculated, 
quantifying the number of people that need to be vaccinated to 
prevent one case of HZ or PHN.
Cost-effectiveness measures. A major constraint faced by all 
national healthcare systems is the limited amount of resource avail-
able. Therefore it is important that budgets are spent on programmes 
that represent value-for-money. Health economics involves the 
study of the efficient allocation of scare health care resources.
In cost-effectiveness analysis (CEA), the difference in cost 
(incremental cost) is compared to the difference in benefits (incre-
mental effect) between the strategy under study and usual care 
from the perspective of a specific payer. That is, if the new policy 
costs more than the comparator policy, does it provide sufficient 
additional benefits (or if a new policy is less effective than the 
comparator, does it offer sufficient cost savings)? CEA provides a 
framework to assist in this decision process. In using the results 
of a CEA, a decision-maker may judge whether a particular cost 
per effect represents acceptable value for money.
Equation 1. Incremental cost-effectiveness ratio
In the present anaysis, the cost-effectiveness of the vaccination 
policy was assessed by comparing the total cost and effective-
ness, measured either by HZ or PHN cases avoided or QALYs 
of both policies. In the situation where the vaccination policy 
Appendix—Health Economic Analysis
Clinical and economic outcomes. In the current analysis clin-
ical and economic results are presented over the lifetime of the 
population following the introduction of the vaccine.
Results are reported for total costs, Quality Adjusted Life 
Years (QALYs), HZ cases and PHN cases (3-month definition) 
under a vaccination policy and a no-vaccination policy. In addi-
tion, Number Needed to Vaccinate (NNV) results have been 
estimated.
QALYs or Quality Adjusted Life Years are often used in 
health economic analyses. QALYs are life years weighted by 
factors representing the utility or preference of individuals for 
health outcomes. These preferences are measured on a scale 
from 0 (death) to 1 (perfect health), so QALYs are derived by 
multiplying the years of survival in a given health state by the 
preference weight for that state. Where progression through a 
series of health states occurs, such as the HZ and PHN states, 
the total QALYs accrued in a lifetime are the sums over time 
spent in each state multiplied by the preference weight for each 
state. There are several instruments for measuring health state 
preferences and utilities (such as SF-36 etc.). Among the generic 
instruments for measuring health-related quality of life, EQ-5D 
is one of the candidate preference-based instruments for use as 
a measure of health outcome. The EQ-5D is a health profile 
describing five domains of health each at three possible levels. 
A tariff of preference values for the 243 individual health states 
which can be described by the EQ-5D has been obtained for 
several countries.1
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is often some threshold ratio above which a strategy would be 
considered not cost-effective.
The cost-effectiveness threshold is represented by the dashed 
line in Figure 1. In Switzerland, there is no official cost-effective-
ness threshold. In this context, the current analysis has assumed 
that health care interventions of less than €30,000 per QALY 
are likely to be considered as cost-effective based on commonly 
accepted cost-effectiveness thresholds in Europe.
Discount rate. Discounting allows the present value of costs 
and outcomes which accrued over the time horizon of the analy-
sis to be appropriately used in calculations.3,4 Thus, as the out-
comes of the analyses are assessed over the lifetime of the Swiss 
population, discount rates have been applied for both costs and 
outcomes (QALYs).
Most reimbursement agencies ask for sensitivity analyses on 
discount rates as, depending on the technology being assessed, 
a change in discount rate can have a major impact on results. 
This is especially the case for vaccines, where the main invest-
ment is made upfront but benefits may be in the distant future. 
Thus alternative discount rates were explored in sensitivity 
analysis.
is both more effective and more costly than the existing policy, 
the incremental cost-effectiveness ratio (ICER) is calculated by 
dividing the difference in total costs between the two vaccina-
tion policies by the difference in effectiveness (see Equation 1). 
Depending on the effectiveness measure used as the denomina-
tor, ICERs in this analysis represent either the cost per HZ/PHN 
case averted or the cost per QALY.
The cost-effectiveness plane is a useful means of considering 
the results of cost-effectiveness analyses. Plotting the incremen-
tal effect on the horizontal axis and the incremental cost on the 
vertical axis defines four ‘quadrants’ of the CE plane that can 
be related to decision-making (see Appendex Fig. 1). Frequently, 
a new treatment strategy falls in the north-east (NE) quadrant, 
where it is both more costly and more effective than the existing 
strategy. In this case, a trade-off between costs and effects has to 
be made in deciding which strategy to employ.
Cost-effectiveness threshold. The advantage of reporting a 
cost per QALY, as opposed to cost per HZ or PHN case averted 
for example, is that it allows comparisons between different types 
of health care programmes. In the interpretation of the incre-
mental cost-effectiveness of different treatment strategies, there 
Figure 1. the cost-effectiveness plane.
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